[Interferon therapy in malignant melanoma].
Recent clinical trials on the systemic application of various forms of interferon in metastatic malignant melanoma showed a moderate response rate of about 11% on an average. Intralesional application of alpha- and beta-interferon, however, resulted in partial or complete regression of the metastases in approx. 50% of the tumors. At present, various combination studies are being carried out in order to enhance the anti-tumor effects of interferon and thus establish a potential therapeutic method in dermato-oncology. In this respect, the combination of alpha-interferon with classic cytostatic drugs (dacarbazine and vindesine) is especially encouraging.
Stadler
R
R
Universitäts-Hautklinik, Klinikum Steglitz der Freien Universität Berlin.
Garbe
C
C
D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D006801:Humans; D015552:Injections, Intralesional; D007372:Interferons / Q000008:administration & dosage*; D008545:Melanoma / Q000628:therapy*; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000628:therapy*
D007372:Interferons
Interferon-Therapie beim malignen Melanom.